Overview

Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

Status:
Recruiting
Trial end date:
2025-04-13
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of AMG 199 in adult subjects and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
Phase:
Phase 1
Details
Lead Sponsor:
Amgen